Figure S1-S4, Table S1-S7 from An Open-label, Multicenter, Single-arm, Phase II Study of Fluzoparib in Patients with Germline &lt;i&gt;BRCA1/2&lt;/i&gt; Mutation and Platinum-sensitive Recurrent Ovarian Cancer

Figure S1-S4, Table S1-S7 from An Open-label, Multicenter, Single-arm, Phase II Study of Fluzoparib in Patients with Germline <i>BRCA1/2</i> Mutation and Platinum-sensitive Recurrent Ovarian Cancer

Ning Li(Shenyang Pharmaceutical University), Lingying Wu(Chang Gung University), Xiaohua Wu(Fudan University Shanghai Cancer Center), Hongyan Guo(Qingdao Agricultural University), Xiaoping Wan(Shanghai First People's Hospital), Quanren Wang, Qiang Wu(Soochow University), Wei Duan(Deakin University), Ruifang An(First Affiliated Hospital of Xi'an Jiaotong University), Rutie Yin(Sichuan University), Hui Zhang(Shihezi University), Xin Zhang(State Forestry and Grassland Administration), Jing Wang(Shanghai Jiao Tong University), Yuting Wang(Tianjin University of Traditional Chinese Medicine), Jihong Liu(Sun Yat-sen University), Qi Zhou(Chongqing University), Ge Lou(Harbin Medical University), Ben Zhang, Jianping Xiong, Kangsheng Gu(Anhui Medical University), Xinfeng Yang, Yuanguang Meng, Hongming Pan, Guiling Li, Hualei Bu(Qilu Hospital of Shandong University), Yaping Zhu, Wenjing Hu, Jianqing Zhu, Li Wang(China Three Gorges University), Shuzhong Yao(Sun Yat-sen University)

Unknown

March 31, 2023

Cited by 0